Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. The average price target represents a -27.73% upside from the last price of $5.54. Looking for new stock ideas? Just click the link above. CytoDyn, a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. 1 Wall Street analysts have issued ratings and price targets for CytoDyn in the last 12 months. CytoDyn in discussions with regulators after CD12 data in COVID-19 Seeking Alpha - 2/22/2021 7:08:24 AM: Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub NewsWire - 2/22/2021 6:18:20 AM: Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. This price target is based on 1 analysts offering 12 month price targets for CytoDyn in the last 3 months. The chart below shows how a company's share price and consensus price target have changed over time. CYDY CytoDyn Inc: CytoDyn Price Target Raised to $3.00/Share From $1.50 by H.C. Wainwright 7:27 am ET April 3, 2020 ( - #5723100 MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. On positive outcome of CD-12 trial what is the consensus of price target? This price target is based on 1 analysts offering 12 month price targets for CytoDyn in the last 3 months. Cytodyn stock price prediction is an act of determining the future value of Cytodyn shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Cytodyn stock future price could yield a significant profit. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Learn more. Message board - Online Community of active, educated investors researching and discussing CytoDyn Inc. Stocks. ... 1 Year Price Target. CYTODYN INC (CYDY) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Read More: https://investorshangout.com/pos - #6068574 Investors should thank Adam Feuerstein for his great research because a $10 billion market capitalization puts a ~$20 price target on CYDY stock. CytoDyn Inc. analyst estimates, including CYDY earnings per share estimates and analyst recommendations. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. CytoDyn price target raised to $4 from $3 at H.C. Wainwright. msn back to msn home money. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All rights reserved. Their average twelve-month price target is $4.00, predicting that the stock has a possible downside of 1.23%. Sign Up to See Ratings...FREE! Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. According to TipRanks.com, Saxon is a 4-star analyst with an average return of 35.7% and a 71.4% success rate. To see all exchange delays and terms of use please see disclaimer. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold.". Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Want to see which stocks are moving? Cytodyn Inc (CYDY:QBB) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. The dark blue line represents the company's actual price. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. The company’s shares closed last Monday at $28.94. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). I Call It A Payday. CytoDyn Inc. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. View which stocks are hot on social media with MarketBeat's trending stocks report. CytoDyn downgraded to Neutral from Buy at H.C. Wainwright 04/28/20 H.C. Wainwright CytoDyn price target raised to $4 from $3 at H.C. Wainwright 04/03/20 H.C. Wainwright CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. In-depth view of key statistics and finances for CYTODYN INC. (CYDY) on MSN Money. Learn more. Previous Next H.C. Wainwright analyst Yi Chen reiterated a Buy rating on CytoDyn (CYDY – Research Report) today and set a price target of $1.50. Shares in Cytodyn Inc are currently priced at $5.54. The Fly. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Price Target Upside/Downside. Based on analysts offering 12 month price targets for CYDY in the last 3 months. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. The average analyst price target of CYDY is higher than 2.61% of stocks in the mid market cap category. Analysts covering Cytodyn Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.03 for the next financial year. Source: Kantar Media, CYDY will report FY 2022 earnings on 07/28/2021, CYDY will report Q3 earnings on 07/28/2021, News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Get daily stock ideas top-performing Wall Street analysts. CytoDyn has an analyst consensus of Hold. CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Learn about financial terms, types of investments, trading strategies and more. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright. CytoDyn Inc () Stock Market info Recommendations: Buy or sell CytoDyn stock? The average price target represents a 36.99% upside from the last price of $2.92. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Export data to Excel for your own analysis. You can unlock it all now. Description: CytoDyn Inc is a US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. SeekingAlpha. View our full suite of financial calendars and market data tables, all for free. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. CYDY CytoDyn Inc: THROW OUT THE FUNDAMENTALS - my price target is $170. Find the latest CYTODYN INC (CYDY) stock quote, history, news and other vital information to help you with your stock trading and investing. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. A high-level overview of CytoDyn Inc. (CYDY) stock. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Get short term trading ideas from the MarketBeat Idea Engine. You can opt out at any time. CytoDyn Inc. analyst ratings, historical stock prices, earnings estimates & actuals. The high price target for CYDY is $4.00 and the low price target for CYDY is $4.00. SI-Bone (SIBN) Needham analyst David Saxon reiterated a Buy rating on SI-Bone today and set a price target of $34.00. The lighter blue line represents the stock's consensus price target. CytoDyn (OTC: CYDY) was reported by HC Wainwright & Co. on 2020-07-06. Component Grades. The Dark Side Of The Electric Vehicle Boom. CytoDyn Inc's variance in analysts' estimates is less than nearly 100% of all US stocks. Analysts. Selvaraju said: “Our 12-month price target is derived Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. We have 9 different ratings for every stock to help you appreciate its future potential. © American Consumer News, LLC dba MarketBeat® 2010-2021. The company’s shares closed last Thursday at $3.08. New finance chief at CytoDyn. The latest price target for . This brand new report is your guide to finding the lithium supply chain winners… including one with a massive new mine.document.write(''); View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Price Target; CytoDyn Inc. (CYDY): $4.05-0.01 (-0.25%) POWR Rating. Receive a free world-class investing education from MarketBeat. Learn everything you need to know about successful options trading with this three-part video course. We see a rather positive sentiment for CytoDyn Inc with 6 Buy predictions and 1 Sell predictions. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. 1 Wall Street analysts have issued ratings and price targets for CytoDyn in the last 12 months. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. … Widespread adoption has Reuters calling this “odd” type of trade the “new Baby Boomer hobby”... but Jim Fink’s “twist” on this trade could hand you $1,295 on average each week from just 9 minutes of “work.” Get the inside scoop on this “$1,295 per week” system... Start Your Risk-Free Trial Subscription Here, Anheuser-Busch Inbev Stock is a Must Own Re-Opening Play, Casey's General Stores is Still a Good Buy, FlexShopper Stock: Small Price, Big Upside, Why Visa (NYSE:V) Stock Deserves More Credit, Thor Industries (NYSE:THO) Deserves A Spot In Your Pantheon Of Stocks, Vertex Should Benefit From a Renewed Focus on Globalization, The REV Group Rockets Higher On 2021 Outlook, Chipotle Continues To Impress Wall Street, ABM Industries Incorporated: High-Demand Service For Reopening Businesses, Texas Roadhouse Looks Like a Post-Pandemic Winner, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, Receive Analysts' Upgrades and Downgrades Daily. Source: FactSet. CytoDyn Inc took a tumble today and lost -€0.250 (-4.670%). Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. 4.00. See what's happening in the market right now with MarketBeat's real-time news feed. The Next Generation of Monoclonal Antibody Therapy. CytoDyn has received no research coverage in the past 90 days. CytoDyn: When More … Home. The company’s shares closed last Monday at $1.10. The high price target for CYDY is $4.00 and the low price target for CYDY is $4.00. There's not enough of this valuable resource to meet demand. CytoDyn stock forecast & analyst price target predictions based on a number of analysts offering 12-months price targets for CYDY in the last 3 months. Find real-time CYDY - Cytodyn Inc stock quotes, company profile, news and forecasts from CNN Business. According to analysts' consensus price target of $4.00, CytoDyn has a forecasted downside of 1.2% from its current price of $4.05. CYDY updated stock price target summary. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv. CytoDyn is committed to enhancing the lives of patients through target specific medicine. Please log in to your account or sign up in order to add this asset to your watchlist. Do Not Sell My Information. But this company might change that... MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CytoDyn Inc (CYDY – Research Report) today and set a price target of $1.50. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 ... Price target. Cytodyn Inc (CYDY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CytoDyn, with a price target of $4.00. All rights reserved. Amount of Analyst Coverage. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Data may be intentionally delayed pursuant to supplier requirements. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for … powered by Microsoft News. I am guessing between $22. International stock quotes are delayed as per exchange requirements. Identify stocks that meet your criteria using seven unique stock screeners. Wall Street Stock Market & Finance report, prediction for the future: You'll find the CytoDyn share forecasts, stock quote and buy / sell signals below.According to present data CytoDyn's CYDY shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). According to TipRanks.com, Chen is a 2-star analyst with Is that way off target? and $25. According to TipRanks.com, Chen is a 5-star analyst with an average return of 22.0% and a 48.1% success rate. Copyright © FactSet Research Systems Inc. All rights reserved. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Fundamental company data provided by Zacks Investment Research. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Their average twelve-month price target is $4.00, predicting that the stock has a possible upside of 70.21%. 1. The company’s shares closed on Friday at $0.50. Fundamental company data and analyst estimates provided by FactSet. CYDY has a higher upside potential (average analyst target price relative to current price) than 8.77% of Pharmaceutical Products stocks. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The Next Short Attack is Coming – Monday The shorts have attacked the character of the CEO, the excessive news flow deemed promotional, the science behind it, and next on their list are results. At that level they are trading at 27.8% premium to the analyst consensus target price of 0.00. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. However, we have a potential of -1.961% for CytoDyn Inc as the target price of €5.00 is below the current price of €5.10.
Apple Watch Formal, Baltimore County Department Of Aging, Gilligan's Island Episodes Season 1, Thrift Stores Downtown Austin, Chalmette Medical Center Closed, Maryland Senior Property Tax Credit, Bromford Housing Pay Rent, Sheffield Pottery Glazes, Deep Roots Native Plant Sale,